Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

56 results

Filters applied: . Clear all
Page 1
Interest in genetic susceptibility testing and disclosure of AD dementia risk in cognitively normal adults: a survey study.
Waterink L, Masselink LA, van der Lee SJ, Visser LNC, Cleutjens S, van der Schaar J, van Harten AC, Scheltens P, Sikkes SAM, van der Flier WM, Zwan MD. Waterink L, et al. Among authors: scheltens p. Alzheimers Res Ther. 2024 Jan 2;16(1):1. doi: 10.1186/s13195-023-01364-w. Alzheimers Res Ther. 2024. PMID: 38167083 Free PMC article.
Most individuals expected they would share their genetic risk with close relatives (77-89%), would participate in medication trials (79-88%), and would make long-term arrangements, e.g. retirement, health care, will (69-82%), with larger proportions for scenarios with high …
Most individuals expected they would share their genetic risk with close relatives (77-89%), would participate in medication trials (79-88%) …
Impact of sharing Alzheimer's disease biomarkers with individuals without dementia: A systematic review and meta-analysis of empirical data.
van der Schaar J, Visser LNC, Ket JCF, Groot C, Pijnenburg YAL, Scheltens P, Bredenoord AL, van den Hoven MA, van der Flier WM. van der Schaar J, et al. Among authors: scheltens p. Alzheimers Dement. 2023 Dec;19(12):5773-5794. doi: 10.1002/alz.13410. Epub 2023 Jul 26. Alzheimers Dement. 2023. PMID: 37496313 Review.
Meta-analysis of five studies including 2012 participants (elevated amyloid = 1324 [66%], asymptomatic = 1855 [92%]) showed short-term psychological impact was not significant (random-effect estimate = 0.10, standard error = 0.23, P = 0.65). ...Personal motivations include …
Meta-analysis of five studies including 2012 participants (elevated amyloid = 1324 [66%], asymptomatic = 1855 [92%]) showed short-term …
Plasma biomarkers predict amyloid pathology in cognitively normal monozygotic twins after 10 years.
den Braber A, Verberk IMW, Tomassen J, den Dulk B, Stoops E, Dage JL, Collij LE, Barkhof F, Willemsen G, Nivard MG, van Berckel BNM, Scheltens P, Visser PJ, de Geus EJC, Teunissen CE. den Braber A, et al. Among authors: scheltens p. Brain Commun. 2023 Feb 4;5(1):fcad024. doi: 10.1093/braincomms/fcad024. eCollection 2023. Brain Commun. 2023. PMID: 36824390 Free PMC article.
Implementation of such biomarkers requires a solid understanding of their long-term dynamics and the contribution of confounding to their association with Alzheimer's disease pathology. ...
Implementation of such biomarkers requires a solid understanding of their long-term dynamics and the contribution of confounding to t …
Amyloid-β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer's disease polygenic risk score.
Tomassen J, den Braber A, van der Lee SJ, Reus LM, Konijnenberg E, Carter SF, Yaqub M, van Berckel BNM, Collij LE, Boomsma DI, de Geus EJC, Scheltens P, Herholz K, Tijms BM, Visser PJ. Tomassen J, et al. Among authors: scheltens p. BMC Neurol. 2022 Dec 15;22(1):484. doi: 10.1186/s12883-022-02925-6. BMC Neurol. 2022. PMID: 36522743 Free PMC article.
Increasingly more risk-full APOE genotype, a high AD-PRS and an abnormal amyloid-beta status were associated with steeper decline in memory functioning in separate models (all p 0.02). A model including 4-way interaction term (APOEAD-PRSamyloid-betatime) was not significan …
Increasingly more risk-full APOE genotype, a high AD-PRS and an abnormal amyloid-beta status were associated with steeper decline in memory …
Acute response to cholinergic challenge predicts long-term response to galantamine treatment in patients with Alzheimer's disease.
Baakman AC, Gavan C, van Doeselaar L, de Kam M, Broekhuizen K, Bajenaru O, Camps L, Swart EL, Kalisvaart K, Schoonenboom N, Lemstra E, Scheltens P, Cohen A, van Gerven J, Groeneveld GJ. Baakman AC, et al. Among authors: scheltens p. Br J Clin Pharmacol. 2022 Jun;88(6):2814-2829. doi: 10.1111/bcp.15206. Epub 2022 Jan 26. Br J Clin Pharmacol. 2022. PMID: 34964149 Free PMC article. Clinical Trial.
In this study, we aimed to investigate the acute pharmacodynamic (PD) effects of administration of a single dose of galantamine on central nervous system (CNS) functioning in mild to moderate AD patients and its potential to predict long-term treatment response. METHODS: T …
In this study, we aimed to investigate the acute pharmacodynamic (PD) effects of administration of a single dose of galantamine on central n …
Multidomain interventions: state-of-the-art and future directions for protocols to implement precision dementia risk reduction. A user manual for Brain Health Services-part 4 of 6.
Solomon A, Stephen R, Altomare D, Carrera E, Frisoni GB, Kulmala J, Molinuevo JL, Nilsson P, Ngandu T, Ribaldi F, Vellas B, Scheltens P, Kivipelto M; European Task Force for Brain Health Services. Solomon A, et al. Among authors: scheltens p. Alzheimers Res Ther. 2021 Oct 11;13(1):171. doi: 10.1186/s13195-021-00875-8. Alzheimers Res Ther. 2021. PMID: 34635167 Free PMC article. Review.
Most trials were conducted in high-income countries. The differences in design between the larger, longer-term trials that met vs. did not meet their primary outcomes suggest that multidomain intervention effectiveness may be dependent on a precision prevention approach, i …
Most trials were conducted in high-income countries. The differences in design between the larger, longer-term trials that met vs. di …
Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status.
Babapour Mofrad R, Scheltens P, Kim S, Kang S, Youn YC, An SSA, Tomassen J, van Berckel BNM, Visser PJ, van der Flier WM, Teunissen CE. Babapour Mofrad R, et al. Among authors: scheltens p. Alzheimers Res Ther. 2021 Jul 26;13(1):133. doi: 10.1186/s13195-021-00873-w. Alzheimers Res Ther. 2021. PMID: 34311775 Free PMC article.
Plasma OAbeta was measured using the multimer detection system (MDS). Long-term storage effects on MDS-OAbeta were assessed using general linear models. ...Additionally, plasma MDS-OAbeta levels appeared affected by long-term storage duration, which could be of inte …
Plasma OAbeta was measured using the multimer detection system (MDS). Long-term storage effects on MDS-OAbeta were assessed using gen …
ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease.
Novak P, Kovacech B, Katina S, Schmidt R, Scheltens P, Kontsekova E, Ropele S, Fialova L, Kramberger M, Paulenka-Ivanovova N, Smisek M, Hanes J, Stevens E, Kovac A, Sutovsky S, Parrak V, Koson P, Prcina M, Galba J, Cente M, Hromadka T, Filipcik P, Piestansky J, Samcova M, Prenn-Gologranc C, Sivak R, Froelich L, Fresser M, Rakusa M, Harrison J, Hort J, Otto M, Tosun D, Ondrus M, Winblad B, Novak M, Zilka N. Novak P, et al. Among authors: scheltens p. Nat Aging. 2021 Jun;1(6):521-534. doi: 10.1038/s43587-021-00070-2. Epub 2021 Jun 14. Nat Aging. 2021. PMID: 37117834 Clinical Trial.
The primary objective was to evaluate the safety and tolerability of long-term AADvac1 treatment. The secondary objectives were to evaluate immunogenicity and efficacy of AADvac1 treatment in slowing cognitive and functional decline. ...
The primary objective was to evaluate the safety and tolerability of long-term AADvac1 treatment. The secondary objectives were to ev …
Tackling challenges in care of Alzheimer's disease and other dementias amid the COVID-19 pandemic, now and in the future.
Mok VCT, Pendlebury S, Wong A, Alladi S, Au L, Bath PM, Biessels GJ, Chen C, Cordonnier C, Dichgans M, Dominguez J, Gorelick PB, Kim S, Kwok T, Greenberg SM, Jia J, Kalaria R, Kivipelto M, Naegandran K, Lam LCW, Lam BYK, Lee ATC, Markus HS, O'Brien J, Pai MC, Pantoni L, Sachdev P, Skoog I, Smith EE, Srikanth V, Suh GH, Wardlaw J, Ko H, Black SE, Scheltens P. Mok VCT, et al. Among authors: scheltens p. Alzheimers Dement. 2020 Nov;16(11):1571-1581. doi: 10.1002/alz.12143. Epub 2020 Aug 12. Alzheimers Dement. 2020. PMID: 32789951 Free PMC article. Review.
We believe this review will provide strategic directions and set standards for health-care leaders in dementia, including governmental bodies around the world in coordinating emergency response plans for protecting and caring for older people with dementia amid the COIVD-19 outbr …
We believe this review will provide strategic directions and set standards for health-care leaders in dementia, including governmental bodie …
Global Burden of Small Vessel Disease-Related Brain Changes on MRI Predicts Cognitive and Functional Decline.
Jokinen H, Koikkalainen J, Laakso HM, Melkas S, Nieminen T, Brander A, Korvenoja A, Rueckert D, Barkhof F, Scheltens P, Schmidt R, Fazekas F, Madureira S, Verdelho A, Wallin A, Wahlund LO, Waldemar G, Chabriat H, Hennerici M, O'Brien J, Inzitari D, Lötjönen J, Pantoni L, Erkinjuntti T. Jokinen H, et al. Among authors: scheltens p. Stroke. 2020 Jan;51(1):170-178. doi: 10.1161/STROKEAHA.119.026170. Epub 2019 Nov 8. Stroke. 2020. PMID: 31699021 Free PMC article.
Conclusions- Global burden of small vessel disease-related brain changes as quantified by an image segmentation tool is a powerful predictor of long-term cognitive decline and functional disability. A combined measure of white matter hyperintensities, lacunar, gray matter, …
Conclusions- Global burden of small vessel disease-related brain changes as quantified by an image segmentation tool is a powerful predictor …
56 results